Zhongshan Cococon Pharmaceutical Co., Ltd.

Primary study objective: To evaluate the bioequivalence of dapoxetine hydrochloride tablets developed and produced by Zhongshan Kekekang Pharmaceutical Co., Ltd. and dapoxetine hydrochloride tablets from Berin-Chemie AG after a single oral administration in healthy Chinese male adult subjects. Secondary objective: To evaluate the safety of the test formulation and the reference formulation in healthy Chinese male adult subjects.

Main research purpose: This study uses Celecoxib Capsules (specification: 0.2 g) of Zhongshan Kekekang Pharmaceutical Co., Ltd. as the test preparation and Celecoxib Capsule (trade name: Celebrex®/Celebrex®, specification: 0.2 g) licensed by G.D.Searle LLC as the reference preparation to investigate the pharmacokinetic parameters of the test preparation and the reference preparation in healthy subjects in the fasting and postprandial states, and evaluate the bioequivalence of the two preparations. Secondary research purpose: To observe the safety of the test preparation and the reference preparation in healthy Chinese subjects.

Primary objective: To compare the differences in the extent and rate of absorption of terazosin hydrochloride tablets (2 mg/tablet) provided by Zhongshan Kekekang Pharmaceutical Co., Ltd. and terazosin hydrochloride tablets (2 mg/tablet, trade name: Gaotling®) produced by Shanghai Abbott Pharmaceutical Co., Ltd. in healthy adults under fasting conditions, and to evaluate their bioequivalence. Secondary objective: To evaluate the safety of terazosin hydrochloride tablets (2 mg/tablet) provided by Zhongshan Kekekang Pharmaceutical Co., Ltd. under fasting conditions.